GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

GSK acquired Nuvalent for $10.6 billion on June 9, 2026, marking its largest-ever acquisition. The deal aims to bolster GSK's oncology portfolio by adding Nuvalent's late-stage lung cancer treatments, zidesamtinib and neladalkib, which are anticipated to launch later in 2026. The acquisition price represents $124 per share in cash for the Boston-based biotech company. Nuvalent specializes in developing cancer drugs, with a focus on three specific lung cancer therapies. This strategic move signals a significant investment by GSK in the cancer drug market under the leadership of its new boss, Luke Miels. The transaction is expected to enhance GSK's presence in the competitive oncology sector.